Characterizing highly benefited patients in randomized clinical trials

DOI10.1515/IJB-2016-0045MaRDI QIDQ6636136FDOQ6636136

Authors: Vivek Charu, Paul B. Rosenberg, Lon Schneider, Lea T. Drye, Lisa Rein, David Shade, Constantine G. Lyketsos, Constantine E. Frangakis 

Publication date: 12 November 2024

Published in: The International Journal of Biostatistics (Search for Journal in Brave)

zbMATH Keywords

RCTAlzheimer's diseaseheterogeneity in treatment effectshigh benefit

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• The central role of the propensity score in observational studies for causal effects
• Estimating individualized treatment rules using outcome weighted learning
• Bayesian inference for causal effects: The role of randomization
• Analysis of randomized comparative clinical trial data for personalized treatment selections
• A robust method for estimating optimal treatment regimes
• Structural nested models and G-estimation: the partially realized promise
• Targeted maximum likelihood learning

This page was built for publication: Characterizing highly benefited patients in randomized clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6636136)